Retatrutide under the microscope.. Potential deaths warn against counterfeit versions of weight-loss drug
Amman4 min read
Share
The drug "Retatrutide," developed by Eli Lilly and showing promising weight-loss results, has raised growing health concerns following reports of two deaths potentially linked to the use of unlicensed versions, according to documents reviewed by CBS News.
Although it has not been proven that these products were the direct cause of the two deaths, the reports highlight the potential risks of purchasing experimental drugs from unreliable sources, especially products sold online without oversight to ensure the safety of their ingredients or the accuracy of their dosages.
Eli Lilly is developing Retatrutide, an experimental drug that targets three hormonal pathways associated with appetite regulation and blood sugar levels, including GLP-1, GIP, and glucagon receptors.
Clinical trials have shown promising results, with participants recording weight loss approaching 30% in some study groups, making it one of the most prominent candidates to revolutionize obesity treatment.
However, the drug still needs to complete the regulatory evaluation process, and it should not be treated as an approved therapy or used in versions circulating outside of licensed clinical trials.
According to reports revealed by CBS News, the first case involved a 41-year-old woman suffering from obesity who died of cardiac arrest after using Retatrutide obtained from an unreliable source.
The second case involves a 49-year-old patient who was reported dead after suffering from severe dehydration, malnutrition, and cardiac arrest after obtaining the product from an online peptide seller.
These reports alone do not prove that the drug was the direct cause of the two deaths, but they raise serious questions regarding the safety of the products used, the conditions under which they were obtained, and the dosages taken.
Concerns were not limited to the reported deaths; other reports indicated health complications in people who used smuggled products bearing the name Retatrutide.
The reported cases included persistent vomiting linked to an esophageal tear, in addition to another case that required hospitalization due to continuous diarrhea for a week.
The problem lies in the fact that products sold outside of approved medical channels may contain substances different from those declared, or inaccurate concentrations, or doses higher than those evaluated in clinical studies.
Severe vomiting and diarrhea can lead to dehydration and electrolyte imbalances, while inappropriate doses can cause serious health complications.
The increasing demand for weight-loss drugs, such as semaglutide used in "Ozempic" and "Wegovy," and tirzepatide used in "Mounjaro" and "Zepbound," has led to the expansion of a market for counterfeit and unlicensed products.
High prices and limited insurance coverage contribute to driving some people to search for cheaper alternatives online, where experimental substances that have not received the necessary regulatory approvals are sometimes sold.
With the rising interest in Retatrutide due to its preliminary results, this activity has extended to products bearing its name despite it not being approved for general use.
These developments confirm the importance of not being swayed by marketing promises, especially when it comes to experimental drugs sold outside of approved medical channels.
Even approved drugs can cause side effects, but using products of unknown origin adds other risks related to the purity of the active ingredient, its concentration, and the actual dosage.
Conclusion: Retatrutide remains a promising experimental drug for treating obesity, but its preliminary results do not justify the use of unlicensed versions. Furthermore, reports of deaths potentially linked to these products do not mean a direct causal relationship has been proven, but rather emphasize the need to investigate the cases and warn against the dangers of drugs from unknown sources.
